EP3176166B1 - Azolbenzolderivat und kristall daraus - Google Patents

Azolbenzolderivat und kristall daraus Download PDF

Info

Publication number
EP3176166B1
EP3176166B1 EP15827218.7A EP15827218A EP3176166B1 EP 3176166 B1 EP3176166 B1 EP 3176166B1 EP 15827218 A EP15827218 A EP 15827218A EP 3176166 B1 EP3176166 B1 EP 3176166B1
Authority
EP
European Patent Office
Prior art keywords
ppm
crystal
compound
crystal according
characteristic peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15827218.7A
Other languages
English (en)
French (fr)
Other versions
EP3176166A1 (de
EP3176166A4 (de
Inventor
Asahi Kawana
Hisae NOZATO
Chikashi KANAZAWA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Pharma Ltd
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Priority to SI201530528T priority Critical patent/SI3176166T1/sl
Priority to RS20190109A priority patent/RS58315B1/sr
Priority to PL15827218T priority patent/PL3176166T3/pl
Priority to MEP-2019-22A priority patent/ME03319B/de
Publication of EP3176166A1 publication Critical patent/EP3176166A1/de
Publication of EP3176166A4 publication Critical patent/EP3176166A4/de
Application granted granted Critical
Publication of EP3176166B1 publication Critical patent/EP3176166B1/de
Priority to HRP20182084TT priority patent/HRP20182084T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • hyperuricemia is considered to be important as a factor of lifestyle diseases associated with obesity, hypertension, dyslipidemia and diabetes or metabolic syndromes, and recently, it has been clarified that hyperuricemia is a risk factor of renal damage, urinary calculi and cardiovascular diseases by epidemiological surveys ( The Guideline Revising Committee of Japanese Society of Gout and Nucleic Acid Metabolism, ed., Guideline for the management of hyperuricemia and gout, second edition, Medical Review (2010 )).
  • a xanthine oxidase inhibitor is expected to be useful for the treatment of diseases associated with active oxygen species by inhibitory activity against the active oxygen species generation, for example, for the treatment of cardiovascular diseases through the vascular function-improving action ( Circulation. 2006; 114: 2508-2516 ).
  • the crystal form A of the compound (I) has peaks at chemical shifts of 116.3 ppm, 117.6 ppm, 120.0 ppm, 123.6 ppm, 125.9 ppm, 127.4 ppm, 143.7 ppm, 151.8 ppm, 161.1 ppm, 162.3 ppm and 165.5 ppm in its solid-state 13 C NMR spectrum.
  • the crystal form A of the compound (I) has a pattern shown in Fig. 5 in its solid-state 13 C NMR spectrum.
  • the crystal form A of the compound (I) has absorption peaks at wave numbers of 745 cm -1 , 822 cm -1 , 889 cm -1 , 975 cm -1 , 997 cm -1 , 1611 cm -1 and 1705 cm -1 in its infrared absorption spectrum (KBr method).
  • the crystal form A of the compound (I) has a pattern shown in Fig. 8 in its infrared absorption spectrum (KBr method).
  • the crystal form B of the compound (I) has a pattern shown in Fig. 2 in its powder X-ray diffraction spectrum.
  • thermogravimetric/differential thermal analysis an "exothermic peak” and an “endothermic peak” are defined as the temperature at the starting point of a peak and mean the exothermic and endothermic starting temperature determined by extrapolation.
  • the exothermic peak” and “endothermic peak” in the TG/DTA may vary a little depending on the measurement conditions.
  • the error is considered to be in the range of ⁇ 5°C or ⁇ 2°C.
  • the crystals identified by the above peaks also include those having peaks within the error range of ⁇ 5°C or ⁇ 2°C.
  • the hydrolysis reaction of the alkyl ester of the compound (I) to the compound (I) proceeds by suspending the alkyl ester of compound (I) in the solvent mentioned above (for example, in an amount of 15 times the amount of the alkyl ester) and then subjecting the suspension to a reaction with a base in an equivalent or slightly excessive amount relative to the alkyl ester.
  • a base in an equivalent or slightly excessive amount relative to the alkyl ester.
  • bases include sodium hydroxide, potassium hydroxide and lithium hydroxide.
  • the reaction proceeds in the range between 0°C and 100°C and is performed preferably in the range between 20°C and 30°C.
  • a method of producing the crystal B of the compound (I) may further comprise a step of subsequently heating the reaction solution.
  • a reaction solution is prepared by adding N,N-dimethylformamide (for example, 10 times the amount of the compound (I)) to the compound (I) and dissolving the mixture by heating and stirring at 80°C.
  • the reaction solution is cooled to the range between 20°C and 30°C and stirred for two hours.
  • the precipitate is filtered out and the filtered product is washed with ethanol (for example, using 10 times the amount of the compound (I)).
  • the mother liquid is allowed to stand in the range between 20°C and 30°C for 7 days and the precipitate is filtered out and dried to obtain crystals.
  • the crystals of the present invention can be identified by a characteristic powder X-ray diffraction spectrum, solid-state 13 C NMR spectrum, infrared absorption spectrum (KBr method) or thermogravimetric/differential thermal analysis (TG/DTA), when other crystal forms are present, the incorporation rate thereof is not referred to.
  • a specific form of crystal is obtained, at least the incorporation of the other crystal forms may be accepted to a degree that cannot be detected by these methods of measurement.
  • a specific form of crystal is used as an active pharmaceutical ingredient for a pharmaceutical agent, it does not mean that the inclusion of the other forms of crystals is unacceptable.
  • the reaction mixture solution was stirred in the range between 20°C and 30°C for one hour and crystals were obtained by filtration.
  • the crystals were vacuum dried at 50°C to yield 811 g of crystals of 4-methyl-2-[4-(2-methylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-1,3-thiazole-5-carboxylic acid.
  • the XRD of the resultant crystals is shown in Fig. 1 .
  • the evaluation of the xanthine oxidase inhibitory activity of the compound (I) was conducted by the method described in the refference ( Method Enzymatic Analysis, 1, 521-522, 1974 ) with partial modification. This evaluation was carried out by measuring oxidase-type xanthine oxidoreductase acrivity. Concretely, a xanthine (manufactured by Sigma Co.) solution was prepared at 10 mM using a 20 mM sodium hydroxide solution and then mixed with 100 mM phosphate buffer to adjusted to 30 ⁇ M. 75 ⁇ L of the solution was added to each well of the 96-well plate.
  • the compound (I) inhibited 70 % or more XO activity at 27 hours after drug administration compared to the control animal at the dose of 10 mg/kg in kidney.
  • the compound (I) inhibited 40 % or more XO activity at 27 hours after drug administration compared to the control animal at the dose of 10 mg/kg in plasma.
  • the compound (I) inhibited 80 % or more XOR activity and XO activity at 24 hours after drug administration compared to the control animal at the dose of 1 mg/kg in liver.
  • the compound (I) inhibited 30 % or more XOR activity at 24 hours after drug administration compared to the control animal at the dose of 1 mg/kg in fat tissues.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (25)

  1. Kristall von 4-Methyl-2-[4-(2-methylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-1,3-thiazol-5-carbonsäure.
  2. Kristall gemäß Anspruch 1, wobei der Kristall kennzeichnende Peaks bei Beugungswinkeln von 2θ (±0,5°) = 8,6°, 10,2°, 13,3°, 14,4°, 18,5°, 19,9°, 21,8°, 25,1°, 25,6°, 26,6°, 27,1° und 29,5° in seinem Pulver-Röntgenbeugungsspektrum aufweist.
  3. Kristall gemäß Anspruch 1, wobei der Kristall kennzeichnende Peaks bei chemischen Verschiebungen (±0,5 ppm) von 116,3 ppm, 117,6 ppm, 120,0 ppm, 123,6 ppm, 125,9 ppm, 127,4 ppm, 143,7 ppm, 151,8 ppm, 161,1 ppm, 162,3 ppm und 165,5 ppm in seinem Festzustand 13C-NMR-Spektrum aufweist.
  4. Kristall gemäß Anspruch 1, wobei der Kristall kennzeichnende Peaks bei Wellenzahlen (±5 cm-1) von 745 cm-1, 822 cm-1, 889 cm-1, 975 cm-1, 997 cm-1, 1611 cm-1 und 1705 cm-1 in seinem Infrarot-Absorptionsspektrum (KBr-Verfahren) aufweist.
  5. Kristall gemäß Anspruch 1, wobei sein exothermer Peak (±5°C) in Thermogravimetrie/Differentialthermoanalyse bei 222°C ist.
  6. Kristall gemäß Anspruch 1, wobei der Kristall kennzeichnende Peaks bei Beugungswinkeln von 2θ (±0,5°) = 10,1°, 12,6°, 13,1°, 14,0°, 18,6°, 24,2°, 25,2°, 25,7°, 27,2° und 30,5° in seinem Pulver-Röntgenbeugungsspektrum aufweist.
  7. Kristall gemäß Anspruch 1, wobei der Kristall kennzeichnende Peaks bei chemischen Verschiebungen (±0,5 ppm) von 115,4 ppm, 118,0 ppm, 119,8 ppm, 123,2 ppm, 126,4 ppm, 129,1 ppm, 142,7 ppm, 151,2 ppm, 160,9 ppm und 166,6 ppm in seinem Festzustand 13C-NMR-Spektrum aufweist.
  8. Kristall gemäß Anspruch 1, wobei der Kristall kennzeichnende Peaks bei Wellenzahlen (±5 cm-1) von 744 cm-1, 810 cm-1, 972 cm-1, 997 cm-1, 1005 cm-1, 1611 cm-1 und 1710 cm-1 in seinem Infrarot-Absorptionsspektrum (KBr-Verfahren) aufweist.
  9. Kristall gemäß Anspruch 1, wobei sein exothermer Peak (±5°C) in Thermogravimetrie/Differentialthermoanalyse bei 225°C ist und es ein wasserfreier Kristall ist.
  10. Kristall gemäß Anspruch 1, wobei der Kristall kennzeichnende Peaks bei Beugungswinkeln von 2θ (±0,5°) = 7,2°, 12,5°, 13,0°, 14,7°, 19,2°, 20,0°, 21,4°, 21,7°, 24,7° und 26,0° in seinem Pulver-Röntgenbeugungsspektrum aufweist.
  11. Kristall gemäß Anspruch 1, wobei der Kristall kennzeichnende Peaks bei chemischen Verschiebungen (±0,5 ppm) von 116,1 ppm, 119,6 ppm, 123,1 ppm, 126,1 ppm, 127,1 ppm, 130,0 ppm, 143,6 ppm, 150,3 ppm, 158,3 ppm, 160,7 ppm, 163,9 ppm, 165,5 ppm und 167,0 ppm in seinem Festzustand 13C-NMR-Spektrum aufweist.
  12. Kristall gemäß Anspruch 1, wobei der Kristall kennzeichnende Peaks bei Wellenzahlen (±5 cm-1) von 745 cm-1, 751 cm-1, 809 cm-1, 820 cm-1, 971 cm-1, 1006 cm-1, 1613 cm-1, 1682 cm-1 und 1710 cm-1 in seinem Infrarot-Absorptionsspektrum (KBr-Verfahren) aufweist.
  13. Kristall gemäß Anspruch 1, wobei sein endothermer Peak (±5°C) bei 88°C und sein exothermer Peak (±5°C) bei 225°C in Thermogravimetrie/Differentialthermoanalyse ist.
  14. Natrium-4-methyl-2-[4-(2-methylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-1,3-thiazol-5-carboxylat.
  15. Kristall der Verbindung gemäß Anspruch 14.
  16. Kristall gemäß Anspruch 15, wobei der Kristall kennzeichnende Peaks bei Beugungswinkeln von 2θ (±0,5°) = 7,2°, 10,9°, 13,3°, 15,9°, 18,2°, 20,8°, 22,1°, 25,2°, 26,1° und 29,1° in seinem Pulver-Röntgenbeugungsspektrum aufweist.
  17. Kristall gemäß Anspruch 15, wobei sein exothermer Peak (±5°C) in Thermogravimetrie/Differentialthermoanalyse bei 281°C ist.
  18. Pharmazeutische Zusammensetzung, welche die Verbindung oder den Kristall gemäß einem der Ansprüche 1 bis 17 und einen pharmazeutisch annehmbaren Träger umfasst.
  19. Verbindung oder Kristall gemäß einem der Ansprüche 1 bis 17 zur Verwendung beim Behandeln oder Verhindern einer Krankheit in Verbindung mit Xanthinoxidase, wobei die Krankheit ausgewählt ist aus der Gruppe bestehend aus Gicht, Hyperurikämie, Tumorlyse-Syndrom, Harnsteinen, Bluthochdruck, Dyslipidämie, Diabetes, kardiovaskulären Erkrankungen, Nierenerkrankungen, Atemwegserkrankungen, entzündlichen Darmerkrankungen, und Autoimmunerkrankungen.
  20. Verfahren zum Herstellen des Kristalls gemäß einem der Ansprüche 2 bis 5, welches die folgenden Schritte umfasst:
    Suspendieren eines Alkylesters von 4-Methyl-2-[4-(2-methylpropoxy)-3-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-1,3-thiazol-5-carbonsäure in einem Lösungsmittel und Durchführen von Hydrolyse durch Zugeben einer wässerigen Lösung einer Base dazu; und
    Neutralisieren des Umsetzungsprodukts.
  21. Verfahren gemäß Anspruch 20, welches ferner den Schritt des Zugebens von Wasser zum neutralisierten Produkt und sein Rühren umfasst.
  22. Verfahren zum Herstellen des Kristalls gemäß Ansprüchen 6 bis 9, welches den Schritt des Suspendierens des Kristalls gemäß Ansprüchen 2 bis 5 in einem Lösungsmittel umfasst.
  23. Verfahren gemäß Anspruch 22, welches ferner den Schritt des Erwärmens der Suspension umfasst.
  24. Verfahren gemäß Anspruch 22 oder 23, wobei das Lösungsmittel ausgewählt ist aus der Gruppe bestehend aus Ethern, Ketonen, Estern, Alkoholen, Wasser und einem Gemisch-Lösungsmittel davon.
  25. Verfahren zum Herstellen des Kristalls gemäß Ansprüchen 10 bis 13, welches Kristallisation aus einer N,N-Dimethylformamidlösung davon umfasst.
EP15827218.7A 2014-07-30 2015-07-29 Azolbenzolderivat und kristall daraus Active EP3176166B1 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SI201530528T SI3176166T1 (sl) 2014-07-30 2015-07-29 Derivat azol benzena in njegov kristal
RS20190109A RS58315B1 (sr) 2014-07-30 2015-07-29 Derivat azol benzena i njegov kristal
PL15827218T PL3176166T3 (pl) 2014-07-30 2015-07-29 Pochodna azolobenzenowa i jej kryształ
MEP-2019-22A ME03319B (de) 2014-07-30 2015-07-29 Azolbenzolderivat und kristall daraus
HRP20182084TT HRP20182084T1 (hr) 2014-07-30 2018-12-10 Derivat azol benzena i njegov kristal

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014155032 2014-07-30
JP2014155030 2014-07-30
PCT/JP2015/071530 WO2016017708A1 (ja) 2014-07-30 2015-07-29 アゾールベンゼン誘導体およびその結晶

Publications (3)

Publication Number Publication Date
EP3176166A1 EP3176166A1 (de) 2017-06-07
EP3176166A4 EP3176166A4 (de) 2017-06-21
EP3176166B1 true EP3176166B1 (de) 2018-11-28

Family

ID=55217605

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15827218.7A Active EP3176166B1 (de) 2014-07-30 2015-07-29 Azolbenzolderivat und kristall daraus

Country Status (31)

Country Link
US (1) US10179780B2 (de)
EP (1) EP3176166B1 (de)
JP (1) JP6279085B2 (de)
KR (1) KR102474325B1 (de)
CN (1) CN106661014B (de)
AU (1) AU2015297501B2 (de)
BR (1) BR112017001657B1 (de)
CA (1) CA2956553C (de)
CY (1) CY1121189T1 (de)
DK (1) DK3176166T3 (de)
ES (1) ES2712850T3 (de)
HR (1) HRP20182084T1 (de)
HU (1) HUE042576T2 (de)
IL (1) IL250143B (de)
LT (1) LT3176166T (de)
ME (1) ME03319B (de)
MX (1) MX370524B (de)
MY (1) MY180730A (de)
NZ (1) NZ729068A (de)
PH (1) PH12017500124B1 (de)
PL (1) PL3176166T3 (de)
PT (1) PT3176166T (de)
RS (1) RS58315B1 (de)
RU (1) RU2701515C2 (de)
SA (1) SA517380787B1 (de)
SG (1) SG11201700741WA (de)
SI (1) SI3176166T1 (de)
TR (1) TR201902314T4 (de)
TW (1) TWI688563B (de)
WO (1) WO2016017708A1 (de)
ZA (1) ZA201700664B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6134072B2 (ja) * 2014-07-30 2017-05-24 帝人ファーマ株式会社 キサンチンオキシダーゼ阻害薬

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0513379T3 (da) * 1990-11-30 1996-09-30 Teijin Ltd 2-Arylthiazolderivater og farmaceutisk præparat indeholdende sådanne
AU703609B2 (en) * 1995-04-07 1999-03-25 Teijin Limited Protective agent for organ or tissue
TR200000458T1 (tr) 1998-06-19 2000-10-23 Teijin Limited 2-(3-siyano-4-izobütiloksifenil)-4-Metil-5-tiazolkarboksilik asit ve bunun üretilmesi için yöntem.
JP2002105067A (ja) 2000-09-28 2002-04-10 Teijin Ltd ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
KR20080066938A (ko) 2005-10-07 2008-07-17 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물
WO2008126770A1 (ja) * 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
WO2008126899A1 (ja) * 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. ５員環へテロ環誘導体及びその医薬用途
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
WO2010128163A2 (en) 2009-05-08 2010-11-11 Pike Pharma Gmbh Small molecule inhibitors of influenza a and b virus and respiratory syncytial virus replication
US20130190366A1 (en) * 2010-02-19 2013-07-25 Cadila Healthcare Limited Substantially pure salts of febuxostat and processes for preparation thereof
US8969582B2 (en) 2010-04-29 2015-03-03 Dr. Reddy's Laboratories Ltd. Preparation of febuxostat
TWI606048B (zh) * 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
US20170247364A1 (en) 2017-08-31
MY180730A (en) 2020-12-08
ES2712850T3 (es) 2019-05-16
KR20170033320A (ko) 2017-03-24
SA517380787B1 (ar) 2021-03-11
JPWO2016017708A1 (ja) 2017-04-27
HUE042576T2 (hu) 2019-07-29
IL250143B (en) 2019-11-28
ME03319B (de) 2019-10-20
SG11201700741WA (en) 2017-02-27
MX2017000412A (es) 2017-04-27
LT3176166T (lt) 2019-01-10
CY1121189T1 (el) 2020-05-29
IL250143A0 (en) 2017-03-30
RS58315B1 (sr) 2019-03-29
RU2701515C2 (ru) 2019-09-27
CA2956553A1 (en) 2016-02-04
KR102474325B1 (ko) 2022-12-05
RU2017106052A (ru) 2018-08-28
NZ729068A (en) 2022-05-27
RU2017106052A3 (de) 2018-08-28
TWI688563B (zh) 2020-03-21
EP3176166A1 (de) 2017-06-07
HRP20182084T1 (hr) 2019-02-08
ZA201700664B (en) 2019-06-26
BR112017001657B1 (pt) 2023-01-17
EP3176166A4 (de) 2017-06-21
JP6279085B2 (ja) 2018-02-14
MX370524B (es) 2019-12-17
WO2016017708A1 (ja) 2016-02-04
TR201902314T4 (tr) 2019-03-21
PH12017500124A1 (en) 2017-05-29
TW201617341A (zh) 2016-05-16
PT3176166T (pt) 2019-02-04
CN106661014A (zh) 2017-05-10
CA2956553C (en) 2023-03-21
BR112017001657A2 (pt) 2018-01-30
PL3176166T3 (pl) 2019-06-28
US10179780B2 (en) 2019-01-15
DK3176166T3 (en) 2019-02-18
PH12017500124B1 (en) 2017-05-29
CN106661014B (zh) 2019-12-24
AU2015297501A1 (en) 2017-03-09
AU2015297501B2 (en) 2019-07-04
SI3176166T1 (sl) 2019-01-31

Similar Documents

Publication Publication Date Title
JP5734532B2 (ja) アゾールベンゼン誘導体
WO2007018137A1 (ja) マルチキナーゼ阻害剤
EP3176165B1 (de) Kristall eines azolbenzolderivats als xanthine oxidase-inhibitor
EP3176166B1 (de) Azolbenzolderivat und kristall daraus
JP6289619B2 (ja) ピリジン誘導体の新規な結晶多形体およびその製造方法
KR20220129450A (ko) 트랜스글루타미나제-2 활성 억제용 벤조이미다졸 유도체 및 이를 함유하는 암 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
17P Request for examination filed

Effective date: 20170227

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

A4 Supplementary search report drawn up and despatched

Effective date: 20170519

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/10 20060101ALI20170515BHEP

Ipc: A61P 9/10 20060101ALI20170515BHEP

Ipc: A61P 9/04 20060101ALI20170515BHEP

Ipc: A61P 35/00 20060101ALI20170515BHEP

Ipc: A61K 31/427 20060101ALI20170515BHEP

Ipc: A61P 1/04 20060101ALI20170515BHEP

Ipc: A61P 11/00 20060101ALI20170515BHEP

Ipc: A61P 19/06 20060101ALI20170515BHEP

Ipc: A61P 37/06 20060101ALI20170515BHEP

Ipc: A61P 43/00 20060101ALI20170515BHEP

Ipc: C07D 417/10 20060101AFI20170515BHEP

Ipc: A61P 9/12 20060101ALI20170515BHEP

Ipc: A61P 13/04 20060101ALI20170515BHEP

Ipc: A61P 13/12 20060101ALI20170515BHEP

Ipc: A61P 1/00 20060101ALI20170515BHEP

Ipc: A61P 1/12 20060101ALI20170515BHEP

Ipc: A61P 3/06 20060101ALI20170515BHEP

DAV Request for validation of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1237345

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20180423

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

INTC Intention to grant announced (deleted)
GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

INTG Intention to grant announced

Effective date: 20181011

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BUGNION S.A., CH

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20182084

Country of ref document: HR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015020625

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1070071

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3176166

Country of ref document: PT

Date of ref document: 20190204

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20190128

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20182084

Country of ref document: HR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190212

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20181128

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E016792

Country of ref document: EE

Effective date: 20190117

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20190400100

Country of ref document: GR

Effective date: 20190422

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2712850

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20190516

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 30120

Country of ref document: SK

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E042576

Country of ref document: HU

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20182084

Country of ref document: HR

Payment date: 20190716

Year of fee payment: 5

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015020625

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20190829

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1070071

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181128

REG Reference to a national code

Ref country code: EE

Ref legal event code: GB1A

Ref document number: E016792

Country of ref document: EE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602015020625

Country of ref document: DE

Representative=s name: HOFFMANN - EITLE PATENT- UND RECHTSANWAELTE PA, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602015020625

Country of ref document: DE

Owner name: TEIJIN LIMITED, OSAKA-SHI, JP

Free format text: FORMER OWNER: TEIJIN PHARMA LIMITED, TOKYO, JP

REG Reference to a national code

Ref country code: LU

Ref legal event code: PD

Owner name: TEIJIN LIMITED; JP

Free format text: FORMER OWNER: TEIJIN PHARMA LIMITED

Effective date: 20200702

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20182084

Country of ref document: HR

Payment date: 20200723

Year of fee payment: 6

REG Reference to a national code

Ref country code: HU

Ref legal event code: GB9C

Owner name: TEIJIN LIMITED, JP

Free format text: FORMER OWNER(S): TEIJIN PHARMA LIMITED, JP

Ref country code: HU

Ref legal event code: FH1C

Free format text: FORMER REPRESENTATIVE(S): DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20200622

Year of fee payment: 6

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: TEIJIN LIMITED; JP

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION

Effective date: 20200804

REG Reference to a national code

Ref country code: NO

Ref legal event code: CHAD

Owner name: TEIJIN LIMITED, JP

REG Reference to a national code

Ref country code: FI

Ref legal event code: PCE

Owner name: TEIJIN LIMITED

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20210617 AND 20210623

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20210628

Year of fee payment: 7

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20182084

Country of ref document: HR

Payment date: 20210721

Year of fee payment: 7

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 1070071

Country of ref document: AT

Kind code of ref document: T

Owner name: TEIJIN LIMITED, JP

Effective date: 20210728

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: TEIJIN LIMITED; JP

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: TEIJIN PHARMA LIMITED

Effective date: 20200804

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20210723

Year of fee payment: 7

Ref country code: CY

Payment date: 20210720

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RS

Payment date: 20210722

Year of fee payment: 7

Ref country code: IS

Payment date: 20210712

Year of fee payment: 7

Ref country code: MT

Payment date: 20210623

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20210706

Year of fee payment: 7

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: TEIJIN LIMITED; JP

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: TEIJIN PHARMA LIMITED

Effective date: 20220629

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20182084

Country of ref document: HR

Payment date: 20220725

Year of fee payment: 8

REG Reference to a national code

Ref country code: HR

Ref legal event code: PPPP

Ref document number: P20182084

Country of ref document: HR

Owner name: TEIJIN LIMITED, JP

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: TEIJIN LIMITED

Effective date: 20221019

REG Reference to a national code

Ref country code: SK

Ref legal event code: PC4A

Ref document number: E 30120

Country of ref document: SK

Owner name: TEIJIN LIMITED, OSAKA-SHI, OSAKA, JP

Free format text: FORMER OWNER: TEIJIN PHARMA LIMITED, TOKYO, JP

Effective date: 20220928

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: TEIJIN LIMITED; JP

Effective date: 20220905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220729

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220729

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20182084

Country of ref document: HR

Payment date: 20230720

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230728

Year of fee payment: 9

Ref country code: RO

Payment date: 20230726

Year of fee payment: 9

Ref country code: NO

Payment date: 20230721

Year of fee payment: 9

Ref country code: IT

Payment date: 20230724

Year of fee payment: 9

Ref country code: ES

Payment date: 20230926

Year of fee payment: 9

Ref country code: EE

Payment date: 20230717

Year of fee payment: 9

Ref country code: CZ

Payment date: 20230721

Year of fee payment: 9

Ref country code: CH

Payment date: 20230801

Year of fee payment: 9

Ref country code: AT

Payment date: 20230720

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20230725

Year of fee payment: 9

Ref country code: SI

Payment date: 20230720

Year of fee payment: 9

Ref country code: SE

Payment date: 20230719

Year of fee payment: 9

Ref country code: PL

Payment date: 20230721

Year of fee payment: 9

Ref country code: HU

Payment date: 20230721

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LV

Payment date: 20230719

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20240621

Year of fee payment: 10

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20182084

Country of ref document: HR

Payment date: 20240718

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240719

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220729

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240719

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220729

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20240722

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240719

Year of fee payment: 10

Ref country code: HR

Payment date: 20240718

Year of fee payment: 10

Ref country code: FI

Payment date: 20240722

Year of fee payment: 10

Ref country code: IE

Payment date: 20240722

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240723

Year of fee payment: 10

Ref country code: DK

Payment date: 20240726

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240725

Year of fee payment: 10

Ref country code: PT

Payment date: 20240718

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20240719

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240730

Year of fee payment: 10